Phase 1 × Melanoma × Endocrine × Clear all
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled
NCT00753415 2015-03-17

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Merck Sharp & Dohme LLC

Phase 1 Completed
37 enrolled 10 charts
NCT00002947 2014-07-02

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Yale University

Phase 1 Terminated
35 enrolled
NCT00006368 2013-05-01

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Novartis

Phase 1 Completed
60 enrolled
NCT00020579 2012-03-15

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
75 enrolled
NCT00667641 2011-05-10

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Rutgers, The State University of New Jersey

Phase 1 Completed
16 enrolled